```
=> S bee(w) venom and rhumato?
L3
             1 BEE(W) VENOM AND RHUMATO?
=> d 13
     ANSWER 1 OF 1 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
L3
AN
     80004448 EMBASE
DN
     1980004448
TI
     [Experimental treatment of rheumatism with local injections of extracts of
       ***RHUMATOLOGIQUE*** D'INJECTIONS LOCALES D'EXTRAIT DE
     UNE EXPERIENCE
     VENIN D'ABEILLES.
AU
     Forestier F.; Palmer M.
CS
     Rhumatologie, (1979) 31/6 (233-236).
SO
     CODEN: RHUMAY
CY
     France
DT
     Journal -
FS
           Drug Literature Index
     037
            Arthritis and Rheumatism
     031
LA
     French
=> s bee(w) venom and lidocaine
L4
            10 BEE(W) VENOM AND LIDOCAINE
=> d 14
L4
     ANSWER 1 OF 10 MEDLINE
AN
     2000136991
                    MEDLINE
     20136991
DN
TI
     Phospholipase A2-induced coagulation abnormalities after bee sting.
     Petroianu G; Liu J; Helfrich U; Maleck W; Rufer R
ΑU
CS
     University of Heidelberg at Mannheim, Department of Pharmacology and
     Toxicology, Germany.. petroia@rumms.uni-mannheim.de
     AMERICAN JOURNAL OF EMERGENCY MEDICINE, (2000 Jan) 18 (1) 22-7.
SO
     Journal code: AA2. ISSN: 0735-6757.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
FS
     Priority Journals
EM
     200004
EW
     20000404
=> d l4 all 1-10
L4
     ANSWER 1 OF 10 MEDLINE
AN
     2000136991
                    MEDLINE
DN
     20136991
TI
     Phospholipase A2-induced coaquiation abnormalities after bee sting.
ΑU
     Petroianu G; Liu J; Helfrich U; Maleck W; Rufer R
CS
     University of Heidelberg at Mannheim, Department of Pharmacology and
     Toxicology, Germany.. petroia@rumms.uni-mannheim.de
     AMERICAN JOURNAL OF EMERGENCY MEDICINE, (2000 Jan) 18 (1) 22-7.
SO
     Journal code: AA2. ISSN: 0735-6757.
```

```
CY . United States
      Journal; Article; (JOURNAL ARTICLE)
· DT
 LA
      English
 FS
      Priority Journals
 EM
      200004
 EW
      20000404
      We will examine the correlation between various
                                                      ***bee***
 AΒ
                      phospholipase A2 (PLA2) concentrations and several
        ***venom***
      parameters of coagulation in human plasma in order to offer a rationale
      for requesting a particular laboratory coagulation test after bee
      sting(s). We will also evaluate in vitro the influence of clinically
      available drugs with a noncompetitive inhibitory effect on PLA2 on the
                                ***bee***
                                              ***venom***
      anticoagulant effect of
                                                            PLA2. Prothrombin
      index (PTi), partial thromboplastin time (PTT), antithrombin III (AT III),
      soluble fibrin monomers (SFM), the activity of coagulation factors I, II,
      V, and VIII, and thrombelastography (TEG) parameters (split point [Sp],
      reaction time [R], kinetic time [K], coagulation time [R + K], maximal
      amplitude [MA], and the growth angle [alpha]) were determined before and
      after addition of 1.4, 2.7, and 4.1 units (1, 2, and 3 microg protein
                         ***bee***
                                       ***venom*** PLA2. Linear regression was
      respectively) of
      used to determine the significance of the relationship between these
      coagulation parameters and ***bee***
                                                ***venom***
                                                               PLA2
      concentrations used. To study the influence of ketamine,
                                                                 ***lidocaine***
      , magnesium, furosemide, and cromolyn on the anticoagulant effect of
                      ***venom***
                                    PLA2, PTi and factor II- and V-activities wer
      measured before and after addition of 2.7 units of PLA2 and PLA2 plus one
      of the tested substances. Determinations of F II, PTi, F V, and F VIII
      showed a negative correlation to ***bee***
                                                       ***venom***
      concentration (r = -0.88, -0.86, -0.81, and -0.79 respectively). A
      positive correlation was found for PTT (r = 0.69). FII- activity and PTi
      correlated better with ***bee***
                                            ***venom***
                                                          PLA2 concentration
      than other parameters. F I, AT III, and SFM showed no changes. Whereas Sp,
      R, and K were prolonged by ***bee***
                                                ***venom***
                                                               PLA2 and a was
      reduced, there was no correlation to the PLA2 concentration. Addition of
      none of the 5 substances could correct the effects of
                                                              ***bee***
        ***venom***
                     PLA2 on the coagulation. In a patient with toxic reaction o
      a severe anaphylactic reaction after bee sting(s) we suggest
      determinations of FII and/or PTi. This will allow a quick and economical
      assessment of coagulation abnormalities after bee sting(s). Noncompetitive
      PLA2-inhibitors (ketamine, ***lidocaine*** , magnesium, furosemide, and
      cromolyn) are unable to correct in vitro the anticoaqulant effect of
                      ***venom***
        ***bee***
                                   PLA2. They cannot be recommended at this stag
      for this purpose. Further investigations with competitive PLA2-inhibitors
      are warranted.
 CT
      Check Tags: Animal; Female; Human; Male; Support, Non-U.S. Gov't
       Antithrombin III: ME, metabolism
        *** Bee Venoms: CH, chemistry***
        ****Bee Venoms: EN, enzymology***
      *Bees
      *Blood Coagulation Disorders: BL, blood
      *Blood Coagulation Disorders: ET, etiology
      *Blood Coagulation Tests: MT, methods
       Cromolyn Sodium: PD, pharmacology
       Drug Screening
       Factor V: ME, metabolism
       Factor VIII: ME, metabolism
       Fibrinogen: ME, metabolism
       Furosemide: PD, pharmacology
      *Insect Bites and Stings: CO, complications
       Ketamine: PD, pharmacology
        *** Lidocaine: PD, pharmacology***
       Linear Models
       Magnesium: PD, pharmacology
```

```
*Phospholipases A: AE, adverse effects
      Phospholipases A: AI, antagonists & inhibitors
      Phospholipases A: AN, analysis
      Phospholipases A: DE, drug effects
      Prothrombin: ME, metabolism
RN
       ***137-58-6 (Lidocaine)***
                                  ; 15826-37-6 (Cromolyn Sodium); 54-31-9
     (Furosemide); 6740-88-1 (Ketamine); 7439-95-4 (Magnesium); 9000-94-6
     (Antithrombin III); 9001-24-5 (Factor V); 9001-26-7 (Prothrombin);
     9001-27-8 (Factor VIII); 9001-32-5 (Fibrinogen)
CN
     EC 3.1.1.- (Phospholipases A); 0 ( ***Bee***
                                                        ***Venoms***
L4
     ANSWER 2 OF 10
                     EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
AN
     2000050514 EMBASE
TI
     Computer-assisted infrared thermographic study of axon reflex induced by
     intradermal melittin.
ΑU
     Koyama N.; Hirata K.; Hori K.; Dan K.; Yokota T.
     N. Koyama, Department of Physiology, Shiga University Medical Sciences,
CS
     Seta, Otsu, Japan. natsu@belle.shiga-med.ac.jp
     Pain, (2000) 84/2-3 (133-139).
SO
     Refs: 29
     ISSN: 0304-3959 CODEN: PAINDB
PUI
     S 0304-3959(99)00192-X
CY
     Netherlands
DT
     Journal; Article
FS
     024
             Anesthesiology
     027
             Biophysics, Bioengineering and Medical Instrumentation
     030
             Pharmacology
     037
             Drug Literature Index
     005
             General Pathology and Pathological Anatomy
     052
             Toxicology
     8 0.0
             Neurology and NeurosurgeryNeurology and Neurosurgery
LA
     English
SL
     English
AB
     The aim of the present study was to investigate whether melittin, the
     principal toxin of the honeybee (Apis mellifera) venom, can be used as an
     algogenic agent in the study of pain in humans. Five micrograms of
     melittin in 0.5 ml of saline was intradermally injected into the volar
     aspect of the forearm. Resultant pain was scored by a visual analogue
     scale (VAS), and skin temperature change was analyzed by means of a
     computer-assisted infrared thermography. Intradermal melittin temporarily
     produced severe pain, followed by a sustained increase in skin
     temperature. The skin temperature increase peaked in about 10 min and
                                                                   gel did not
     outlasted 1 h. Topical application of 10%
                                                 ***lidocaine***
     significantly suppress the melittin-induced pain, but markedly suppressed
     both the increase in the peak temperature and the area of temperature
     increase. In conclusion, 5 .mu.g of melittin is sufficient to produce pain
     in humans and 10%
                         ***lidocaine***
                                           gel differentially decreases the
     melittin-induced axon reflex without any significant analgesic effect.
     Copyright (C) 2000 International Association for the Study of Pain.
     Published by Elsevier Science B.V.
CT
     Medical Descriptors:
     *pain: DT, drug therapy
     *skin temperature
     reflex
     nerve fiber
     rating scale
     infrared photography
     thermography
     computer assisted diagnosis
     dose time effect relation
     gel
     nerve fiber C
     visual analogue scale
```

```
    axon reflex

     human
     male
     female
     human experiment
     normal human
     controlled study
     aged
     adult
     clinical trial
     article
     priority journal
     Drug Descriptors:
     *melittin: TO, drug toxicity
       ****lidocaine: PD, pharmacology***
       ****lidocaine: PR, pharmaceutics***
       ****lidocaine: DT, drug therapy***
       ****lidocaine: TP, topical drug administration***
       ***bee venom: TO, drug toxicity***
RN
     (melittin) 20449-79-0, 37231-28-0, 65742-02-1; ( ***lidocaine*** )
     137-58-6, 24847-67-4, 56934-02-2, 73-78-9
                    EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
L4
     ANSWER 3 OF 10
AN
     2000049945 EMBASE
TI
     Phospholipase A2-induced coagulation abnormalities after bee sting.
AU
     Petroianu G.; Liu J.; Helfrich U.; Maleck W.; Rufer R.
CS
     Dr. G. Petroianu, University of Heidelberg at Mannheim, Dept. of
     Pharmacology and Toxicology, Maybach Street 14-16, 68169 Mannheim,
     Germany. petroia@rumms.uni-mannheim.de
SO
     American Journal of Emergency Medicine, (2000) 18/1 (22-27).
     ISSN: 0735-6757
                      CODEN: AJEMEN
CY
     United States
DT
     Journal; Article
FS
            Hematology
     052
             Toxicology
LA
     English
SL
     English
                                                      ***bee***
AB
     We will examine the correlation between various
                     phospholipase A2 (PLA2) concentrations and several
     parameters of coaquiation in human plasma in order to offer a rationale
     for requesting a particular laboratory coagulation test after bee
     sting(s). We will also evaluate in vitro the influence of clinically
     available drugs with a noncompetitive inhibitory effect on PLA2 on the
     anticoagulant effect of
                               ***bee***
                                             ***venom*** PLA2. Prothrombin
     index (PTi), partial thromboplastin time (PTT), antithrombin III (AT III),
     soluble fibrin monomers (SFM), the activity of coagulation factors I, II,
     V, and VIII, and thrombelastography (TEG) parameters (split point [Sp],
     reaction time [R], kinetic time [K], coagulation time [R + K], maximal
     amplitude [MA], and the growth angle [.alpha.]) were determined before and
     after addition of 1.4, 2.7, and 4.1 units (1, 2, and 3 .mu.g protein
                        ***bee***
                                      ***venom*** PLA2. Linear regression was
     respectively) of
     used to determine the significance of the relationship between these
     coagulation parameters and
                                  ***bee***
                                                ***venom***
     concentrations used. To study the influence of ketamine,
                                                                ***lidocaine***
      magnesium, furosemide, and cromolyn on the anticoagulant effect of
       ***bee***
                     ***venom***
                                   PLA2, PTi and factor II- and V-activities wer
     measured before and after addition of 2.7 units of PLA2 and PLA2 plus one
     of the tested substances. Determinations of F II, PTi, F V, and F VIII
                                        ***bee***
     showed a negative correlation to
                                                      ***venom***
     concentration (r = -0.88, -0.86, -0.81, and -0.79 respectively). A
     positive correlation was found for PTT (r = 0.69). FII- activity and PTi
     correlated better with
                             ***bee***
                                           ***venom***
                                                         PLA2 concentration
```

```
· than other parameters. F I, AT III, and SFM showed no changes. Whereas Sp,
 R, and K were prolonged by ***bee*** ***venom***
                                                          PLA2 and .alpha.
 was reduced, there was no correlation to the PLA2 concentration. Addition
 of none of the 5 substances could correct the effects of
   ***venom***
                 PLA2 on the coaquiation. In a patient with toxic reaction o
 a severe anaphylactic reaction after bee sting(s) we suggest
 determinations of FII and/or PTi. This will allow a quick and economical
 assessment of coagulation abnormalities after bee sting(s). Noncompetitive
 PLA2-inhibitors (ketamine, ***lidocaine*** , magnesium, furosemide, and
 cromolyn) are unable to correct in vitro the anticoagulant effect of
    ***bee***
                  ***venom***
                               PLA2. They cannot be recommended at this stag
 for this purpose. Further investigations with competitive PLA2-inhibitors
 are warranted. Copyright (C) 2000 W.B. Saunders Company.
 Medical Descriptors:
 *blood clotting disorder: ET, etiology
 *bee sting: ET, etiology
  *enzyme analysis
 pathogenesis
 blood clotting test
 protein analysis
 concentration (parameters)
 correlation function
 human
 male
 female
 clinical article
 human experiment
 human tissue
 article
 priority journal
 Drug Descriptors:
  *phospholipase A2: EC, endogenous compound
 ketamine
   ***lidocaine***
 magnesium
 furosemide
 cromoglycate disodium
  (phospholipase A2) 9001-84-7; (ketamine) 1867-66-9, 6740-88-1, 81771-21-3;
    ***lidocaine*** ) 137-58-6, 24847-67-4, 56934-02-2, 73-78-9;
  (magnesium) 7439-95-4; (furosemide) 54-31-9; (cromoglycate disodium)
 15826-37-6, 16110-51-3, 93356-79-7, 93356-84-4
                 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
 ANSWER 4 OF 10
 1999002361 EMBASE
 The contribution of spinal neuronal changes to development of prolonged,
 tonic nociceptive responses of the cat induced by subcutaneous
    ***venom***
                  injection.
 Chen J.; Luo C.; Li H.-L.
 Dr. J. Chen, Department of Anatomy, K. K. Leung Brain Research Center,
 Fourth Military Medical University, 17 West Chang-le Road, Xi'an 710032,
 European Journal of Pain, (1998) 2/4 (359-376).
 Refs: 53
 ISSN: 1090-3801 CODEN: EJPAFJ
 United Kingdom
 Journal; Article
 005
         General Pathology and Pathological Anatomy
 800
         Neurology and Neurosurgery
 English
 English
 To elucidate neurophysiological mechanisms of persistent pain induced by
 tissue injury, the present study was designed to investigate the effects
 of s.c.
           ***bee***
                         ***venom***
                                        injection on responses of the dorsal
```

CT

RN

L4

AN

TI

ΑU

CS

SO

CY

DT

FS

LA SL

AB

```
    horn nociceptive neurons and those of behavior in anesthetized and awake

 cats, respectively. A parallel comparative study was also performed to
 compare the effects of s.c.
                                              ***venom***
                               ***bee***
                                                            and formalin
 injections on neuronal responses by using an extracellular single-unit
 recording technique. The present results showed that s.c.
    ***venom***
                 injection into the peripheral cutaneous receptive field
 resulted in a protracted, tonic monophase of increase in spike responses
 of wide-dynamic-range (WDR) neurons for more than 1 h, while injection of
 the same volume of vehicle did not have such an effect. The mean number of
 spikes during the 60-min period after
                                          ***bee*.**
                                                        ***venom***
 6.74.+-.2.58 spikes/s (n= 10), which showed a significant increase in
 firing rate over the background activity (2.23 .+-. 0.96 spikes/s).
 Behavioral observations showed that s.c. ***bee***
 injection into the dorsum of a hind paw also produced a prolonged, tonic
 single phase of response indicative of pain, suggesting that central
 neuronal changes may contribute to development of
                                                     ***bee***
    ***venom*** -induced prolonged, tonic pain in cats. The increased
 neuronal firing induced by s.c.
                                   ***bee***
                                                 ***venom***
 suppressed by a single dose of i.v. morphine and resumed by naloxone.
                                      ***lidocaine***
 Blockade of the sciatic nerve with
                                                         resulted in a
 complete suppression of the ***bee***
                                             ***venom*** -induced neuronal
 firing, suggesting that the central neuronal changes following s.c.
    ***bee***
                 ***venom***
                               are peripherally-dependent. Comparative
 studies showed that the duration and frequency of the
                                                          ***bee***
   ***venom*** -induced neuronal responses were comparable to those induced
 by s.c. formalin; however, responses of WDR neurons to mechanical stimuli
 applied to the injection site of the two chemical agents were quite
              ***Bee***
                            ***venom*** produced a significant
 enhancement of mechanical responses of WDR neurons, while, on the
 contrary, formalin produced a desensitization of sensory receptors in the
 injection site, suggesting that the two tonic pain models may have
 different underlying mechanisms.
 Medical Descriptors:
 *nociception
 *neurophysiology
 *pain: ET, etiology
 tissue injury
 spinal cord dorsal horn
 cat
 animal behavior
 nerve cell
 pain assessment
 desensitization
 sensory receptor
 pathophysiology
 electrophysiology
 neuromodulation
 nonhuman
 male
 female
 animal experiment
 animal model
 controlled study
 article
 priority journal
 Drug Descriptors:
   ****bee venom***
 morphine
 n methyl dextro aspartic acid: EC, endogenous compound
  (morphine) 52-26-6, 57-27-2; (n methyl dextro aspartic acid) 6384-92-5
 ANSWER 5 OF 10 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
```

AN 83058327 EMBASE

CT

RN

L4

```
DN \cdot
     1983058327
TI
     [Anaphylactic shock. Results of a national study of 1047 cases].
     LE CHOC ANAPHYLACTIQUE. RESULTATS D'UNE ENQUETE NATIONALE PORTANT SUR 1047
ΑU
     Mantz J.M.; Pauli G.; Meyer P.; et al.
CS
     Serv. Reanim. Med., Hosp. Civ., 67091 Strasbourg, France
     Revue de Medecine Interne, (1982) 3/4 (331-338).
SO
     CODEN: RMEIDE
CY
     France
DΤ
     Journal
FS
     038
             Adverse Reactions Titles
     006
             Internal Medicine
     026
             Immunology, Serology and Transplantation
     024
             Anesthesiology
     037
             Drug Literature Index
             Cardiovascular Diseases and Cardiovascular Surgery
     018
LA
     French
SL
     English
     Results of a multicentric French study of 1047 cases of anaphylactic shock
AB
     seen during the past 6 years are reported. Anesthetics and curarizing
     drugs, hymenoptera venoms, analgesics, iodine-containing contrast products
     and antibiotics are responsible for 75% of the cases. Hyperacute forms of
     anaphylactic shock, clinically manifested by cardiovascular signs, are
     represented by one third of the cases in the series. The remaining two
     thirds concern subacute cases dominated by cutaneous, respiratory,
     digestive or neurological signs. In half the cases, anaphylactic shock
     developed less than 5 minutes after contact with the allergen. Contrary to
     widespread opinion, there exists a correlation between the severity of the
     clinical state and certain laboratory parameters (leukopenia, lowering of
     serum complement). Diverse therapeutic measures were employed;
     corticotherapy was applied in 90% of the cases, adrenaline in only 16%.
     The authors deplore the loss of 32 of the 1047 patients (3%).
CT
     Medical Descriptors:
     *adverse drug reaction
     *alfadione
     *anaphylactic shock
     *betoxycaine
     *blood
    *drug hypersensitivity
     *nortoxiferrine
     *drug therapy
     *plasma
     blood and hemopoietic system
     therapy
     intravenous drug administration
     cardiovascular system
     epidemiology
     Drug Descriptors:
     *acetylsalicylic acid
     *adrenalin
     *aminophenazone
     *analgesic agent
     *anesthetic agent
     *antibiotic agent
       ****bee venom***
     *cephalosporin derivative
     *contrast medium
     *corticosteroid derivative
     *corticotropin
     *cyanocobalamin
     *dextran
```

\*dobutamine

=> s kim(w)c(m)

MISSING OPERATOR 'W) C (M'

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s kim(w)c(w)m

L5 0 KIM(W) C(W) M

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	$\mathtt{TOTAL}$
	ENTRY	SESSION
FULL ESTIMATED COST	83.74	84.04
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
Discount Industry (Loss Southern Line Meconity)	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.56	-0.56

STN INTERNATIONAL LOGOFF AT 16:42:50 ON 22 SEP 2000

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:ssspta1644pnh

PASSWORD:

NEWS INTER NEWS LOGIN

NEWS PHONE

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* * *	* *	* *	* Welcome to STN International * * * * * * * * *		
NEWS	3 1			Web Page URLs for STN Seminar Schedule - N. America		
NEWS	5 2	Aug	21	Instant Access to FDA Regulatory Information with DIOGENES		
NEWS	3	Aug	21	CAS patent coverage expanded		
NEWS	3 4			TABULATE Now Available in More STN Databases		
NEWS	5 5	Aug	28	MEDLINE from 1958 to Date - Only on STN		
NEWS			7			
				Searching of Biosequences		
NEWS	5 7	Sep	11	Textile Technology Digest (TEXTILETECH) now available on STN		
NEWS	8	Sep	21	KKF renamed DKILIT		
NEWS EXPRESS		FREE UPGRADE 5.0D FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE				
NEWS HOURS		ST	STN Operating Hours Plus Help Desk Availability			

Direct Dial and Telecommunication Network Access to STN

General Internet Information

Welcome Banner and News Items

Structure search limits have been increased. See HELP SLIMIT for details.

=> file biosis embase caplus medline toxlet scisearch

'TOXLET' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):end

=> file embase biosis medline caplus scisearch

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.90 9.75

FULL ESTIMATED COST

FILE 'EMBASE' ENTERED AT 17:07:14 ON 22 SEP 2000 COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:07:14 ON 22 SEP 2000 COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 17:07:14 ON 22 SEP 2000

FILE 'CAPLUS' ENTERED AT 17:07:14 ON 22 SEP 2000 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 17:07:14 ON 22 SEP 2000 COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

=> s bee(w) venom and ?arthris

L3 0 BEE(W) VENOM AND ?ARTHRIS

=> s bee

L4 40968 BEE

=> s 14 and venom?

L5 8352 L4 AND VENOM?

=> s 15 and (?arthritis)

L6 126 L5 AND (?ARTHRITIS)

=> s 16 and (lidocain or 137-58-6)

L7 0 L6 AND (LIDOCAIN OR 137-58-6)

=> s 16 and pain

L8 10 L6 AND PAIN

=> d 18

```
L8 .
    ANSWER 1 OF 10
                    EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
AN
     2000278919 EMBASE
                                               ***pain*** relief.
TI
       ***Bee***
                     ***venom***
                                    provides
     Manufacturing Chemist, (2000) 71/8 (11).
SO
     ISSN: 0262-4230 CODEN: MCHMDI
CY
     United Kingdom
DT
     Journal; Note
FS
     030
             Pharmacology
     031
             Arthritis and Rheumatism
     037
             Drug Literature Index
LA
     English
=> d 18 all 1-10
L8
                             COPYRIGHT 2000 ELSEVIER SCI. B.V.
     ANSWER 1 OF 10
                     EMBASE
AN
     2000278919 EMBASE
ΤI
       ***Bee***
                     ***venom***
                                               ***pain***
                                    provides
                                                             relief.
SO
     Manufacturing Chemist, (2000) 71/8 (11).
     ISSN: 0262-4230 CODEN: MCHMDI
CY
     United Kingdom
DT
     Journal; Note
FS
     030
             Pharmacology
     031
             Arthritis and Rheumatism
     037
             Drug Literature Index
LΑ
     English
     Medical Descriptors:
CT
     *analgesia
     New Zealand
       ***arthritis: DT, drug therapy***
     drug marketing
     diet supplementation
     hormone synthesis
     antiinflammatory activity
     human
     clinical trial
     note
     Drug Descriptors:
       ****bee venom: CT, clinical trial***
       ****bee venom: DT, drug therapy***
       ****bee venom: PD, pharmacology***
     honey: DT, drug therapy
     nectar ease
RN
     (honey) 8028-66-8
CN
     (1) Nectar ease
CO
     (1) Nelson
L8
     ANSWER 2 OF 10 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
AN
     1999425740 EMBASE
TI
     Beekeepers' arthropathy.
ΑU
     Cuende E.; Fraguas J.; Pena J.E.; Pena F.; Garcia J.C.; Gonzalez M.
CS
     Dr. E. Cuende, Unidad de Reumatologia, Hospital Txagorritxu, Jose
     Atxotegui s/n, 01009 Vitoria, Spain
SO
     Journal of Rheumatology, (1999) 26/12 (2684-2690).
     Refs: 26
     ISSN: 0315-162X CODEN: JRHUA
CY
     Canada
DT
     Journal; Article
FS
     017
             Public Health, Social Medicine and Epidemiology
     031
             Arthritis and Rheumatism
     035
             Occupational Health and Industrial Medicine
LA
     English
```

```
SL ·
     English
     Objective. To describe the clinical, analytical, and radiological features
AB -
     of an observed arthropathy affecting beekeepers. Methods. Prospective
     study of 34 patients (32 male, 2 female), mean age 42 years (range 16 to
     66 years), evaluated for the presence of acute or chronic
                        related to beekeeping. All patients were working and
       ***arthritis***
     living in the same village, Fuenlabrada de los Montes (1300 habitants),
     where there is a census of 180 beekeepers. An epidemiologic inquiry
     reported that > 50% of them reported episodes of ***arthritis***
     the hands during the month of August, at the time of honey collection.
     Results. Acute
                      ***arthritis***
                                       was observed in 10 patients.
       ***Pain***
                  , tenderness, joint swelling, and warmth were present in most
     cases. Chronic arthropathy was noted in 32 patients. Tenderness was
     present in 16 cases, synovial thickening in 12, limited joint mobility in
     8, bony swelling in 15, and joint deformities in 13 patients. Radiological
     study showed periarticular soft tissue swelling, bone sclerosis,
     periostitis, bony erosions, subchondral cysts, geodes, osteophytes, and
     joint narrowing. Conclusion. Beekeepers have joint disease apparently
                  ***bee***
                              stings. Etiopathogenesis is unknown. Mechanical
     related to
               ***venom***
                             compounds, infection, and foreign body synovitis
     are factors that are thought to influence the pathogenesis of this
     syndrome. We designate the condition 'beekeepers' arthropathy,' and
     consider it an occupational disorder.
CT
     Medical Descriptors:
     *arthropathy: EP, epidemiology
     *arthropathy: ET, etiology
     *occupational disease: EP, epidemiology
     *occupational disease: ET, etiology
       ****bee sting***
     pathogenesis
     prevalence
     clinical feature
     joint mobility
       ***pain assessment***
     human
     male
     female
     clinical article
     aged
     adult
     article
     priority journal
L8
     ANSWER 3 OF 10
                    EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
AN
     90302592 EMBASE
DN
     1990302592
TI
       ***Bee***
                     ***venom***
                                   therapy for chronic
                                                          ***pain***
ΑU
     Klinghardt D.K.
CS
     1468 Saint Francis Drive, Santa Fe, NM 87501, United States
SO
     Journal of Neurological and Orthopaedic Medicine and Surgery, (1990) 11/3
     (195-197).
     ISSN: 0890-6599 CODEN: JOMSEB
CY
     United States
DT
     Journal; Conference Article
FS
     800
             Neurology and Neurosurgery
     033
             Orthopedic Surgery
     037
             Drug Literature Index
LA
     English
CT
     Medical Descriptors:
     *intervertebral disk hernia: DT, drug therapy
       ****intractable pain: DT, drug therapy***
       ****low back pain: DT, drug therapy***
       ****rheumatoid arthritis: DT, drug therapy***
```

```
adult
human
male
female
intradermal drug administration
conference paper
Drug Descriptors:
  ****bee venom: DT, drug therapy***
ANSWER 4 OF 10
                EMBASE
                        COPYRIGHT 2000 ELSEVIER SCI. B.V.
78157606 EMBASE
1978157606
The pharmacological activity of tribenoside.
Jaques R.
Res. Dept., Pharmaceut. Div., Ciba Geigy, Basel, Switzerland
Pharmacology, (1977) 15/5 (445-460).
CODEN: PHMGBN
Switzerland
Journal
037
        Drug Literature Index
030
        Pharmacology
English
Ethyl-3,5,6-tri-O-benzyl-D-glucofuranoside (tribenoside), the active
substance of Glyvenol, displays a unique spectrum of activities. It
possesses anti-inflammatory, mild analgesic, antitoxic, wound-healing,
fibrinolysis- promoting, anti-arthrotic, amine-release-inhibitory,
membrane-stabilizing and venotropic properties. Unlike corticosteroids or
non-steroidal anti-inflammatory agents, tribenoside does not exert
untoward effects on the gastro-intestinal system, the connective tissue or
the body's defence systems. In addition, tribenoside does not affect the
prostaglandin-synthetase system. Tribenoside thus seems to share the
positive pharmacological properties ascribed to glucocorticoids and
non-steroidal anti-inflammatory agents, yet is free from the undesirable
effects of both.
Medical Descriptors:
  ****arthritis***
*arthrosis
*fibrinolysis
*inflammation
  ****pain***
*wound healing
review
Drug Descriptors:
*amine
*aminophenazone
*analgesic agent
*anaphylatoxin
  ****bee venom***
*bradykinin
*substance p
*compound 48-80
*corticotropin derivative
*hydrocortisone
*metformin
*ovalbumin
*oxprenolol
*phenylbutazone
*thrombocyte cr 51.
*propranolol
*salicylic acid
*tetracosactide
*tribenoside
```

L8

ΑN

DN

TI

ΑU

CS

SO

CY

DT

FS

LA

AB

CT

\*\*\*\*wasp venom\*\*\*

```
radioisotope
     c44680 ba
     unclassified drug
     (aminophenazone) 58-15-1, 8058-63-7; (bradykinin) 58-82-2, 5979-11-3;
RN
     (substance p) 33507-63-0; (hydrocortisone) 50-23-7; (metformin) 1115-70-4,
     657-24-9; (ovalbumin) 77466-29-6; (oxprenolol) 22972-97-0, 6452-71-7,
     6452-73-9; (phenylbutazone) 129-18-0, 50-33-9, 8054-70-4; (propranolol) 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (salicylic acid)
     63-36-5, 69-72-7; (tetracosactide) 16960-16-0; (tribenoside) 10310-32-4
CN
     Glyvenol; Synacthen; C44680 ba
L8
     ANSWER 5 OF 10
                      EMBASE
                              COPYRIGHT 2000 ELSEVIER SCI. B.V.
ΑN
     75023135 EMBASE
DN
     1975023135
     A study of the therapeutic value of electrophoresis with
ΤI
                                                                   ***bee***
                     ('mellivenon') in children with rheumatoid
                                                                    ***arthritis**
     (Bulgarian).
ΑU
     Nikolova V.
CS
     Bulgaria
SO .
     PROBL. PEDIAT., (1973) Vol. 16/- (101-106).
     CODEN: XXXXXB
DT
     Journal
FS
     037
             Drug Literature Index
     007
             Pediatrics and Pediatric Surgery
     031
             Arthritis and Rheumatism
     030
             Pharmacology
LA
     Bulgarian
AB
     Mellivenon was introduced by electrophoresis into the affected joints of
     18 children with rheumatoid
                                    ***arthritis*** .
                                                          ***Bee***
                     is a complex mixture of biologic substances, including
       ***venom***
     melletin, apamine, hyaluronidase and phospholipase A, which have a local
     analgesic, hyperemia inducing, and antiinflammatory effect and stimulate
     the pituitary adrenal system, followed by enhanced secretion of adrenal
     corticotrophic hormone and cortisone. Treatment was carried out, in
     conjunction with the maintenance antirheumatic drug therapy previously
     given for months without much effect. The untoward reactions were
     observed. The joint
                           ***pains***
                                          abated and even completely
     disappeared; joint deformities improved in 48 cases and the extent of
     movement in 39. Rheumatic activity was reduced in children with moderate
     and minimal activity, but was unaffected in severely active cases. With
     the exception of 2 patients with high rheumatoid activity whose basic
     inflammatory process was further activated, it was possible to reduce the
     dose of maintenance hormonal treatment in 4 patients, to discontinue it in
     2 and to reduce all other antirheumatic therapy, aspirin, amidopyrine,
     analgin and resochin in 8 patients.
CT
     Medical Descriptors:
     *clinical study
     *corticotropin release
     *drug screening
     *hyperemia
     *hypophysis adrenal system
     *inflammation
     *joint
     *pharmacology
       ****rheumatoid arthritis***
     major clinical study
     therapy
     intraarticular drug administration
     Drug Descriptors:
     *acetylsalicylic acid
     *aminophenazone
     *analgesic agent
```

```
*antiinflammatory agent
       ****bee venom***
     *chloroquine
    *cortisone
     *dipyrone
     mellivenon
     unclassified drug
     (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6,
RN
     63781-77-1; (aminophenazone) 58-15-1, 8058-63-7; (chloroquine) 132-73-0,
     3545-67-3, 50-63-5, 54-05-7; (cortisone) 53-06-5; (dipyrone) 50567-35-6,
     5907-38-0, 68-89-3
CN
     Mellivenon; Analgin; Aspirin; Resochin; Amidopyrine
CO
     Pharmachim (Bulgaria)
     ANSWER 6 OF 10 BIOSIS COPYRIGHT 2000 BIOSIS
L8
AN
     2000:54659 BIOSIS
DN
     PREV20000054659
TI
     Beekeepers' arthropathy.
ΑU
     Cuende, Eduardo (1); Fraguas, Jesus; Pena, Juan Enrique; Pena, Fernando;
     Garcia, Juan Carlos; Gonzalez, Manuel
CS
     (1) Unidad de Reumatologia, Hospital Txagorritxu, Jose Atxotegui s/n,
     01009, Vitoria Spain
SO
     Journal of Rheumatology, (Dec., 1999) Vol. 26, No. 12, pp. 2684-2690.
     ISSN: 0315-162X.
DT
     Article
LA
     English
SL
     English
AΒ
     Objective: To describe the clinical, analytical, and radiological features
     of an observed arthropathy affecting beekeepers. Methods: Prospective
     study of 34 patients (32 male, 2 female), mean age 42 years (range 16 to
     66 years), evaluated for the presence of acute or chronic
       ***arthritis***
                        related to beekeeping. All patients were working and
     living in the same village, Fuenlabrada de los Montes (1300 habitants),
     where there is a census of 180 beekeepers. An epidemiologic inquiry
     reported that > 50% of them reported episodes of
                                                        ***arthritis***
     the hands during the month of August, at the time of honey collection.
                     ***arthritis***
     Results: Acute
                                      was observed in 10 patients.
       ***Pain***
                  , tenderness, joint swelling, and warmth were present in most
     cases. Chronic arthropathy was noted in 32 patients. Tenderness was
     present in 16 cases, synovial thickening in 12, limited joint mobility in
     8, bony swelling in 15, and joint deformities in 13 patients. Radiological
     study showed periarticular soft tissue swelling, bone sclerosis,
     periostitis, bony erosions, subchondral cysts, geodes, osteophytes, and
     joint narrowing. Conclusion: Beekeepers have joint disease apparently
     related to
                  ***bee***
                              stings. Etiopathogenesis is unknown. Mechanical
               ***venom***
                            compounds, infection, and foreign body synovitis
     are factors that are thought to influence the pathogenesis of this
     syndrome. We designate the condition "beekeepers' arthropathy," and
     consider it an occupational disorder.
CC
     Bones, Joints, Fasciae, Connective and Adipose Tissue - General; Methods
     *18001
     Pathology, General and Miscellaneous - Diagnostic
                                                        *12504
     Immunology and Immunochemistry - General; Methods
BC
     Hominidae
                 86215
IT
     Major Concepts
        Occupational Health (Allied Medical Sciences); Rheumatology (Human
        Medicine, Medical Sciences)
IT
     Parts, Structures, & Systems of Organisms
        periarticular soft tissue: connective tissue, inflammation
IT
        beekeeper's arthropathy: joint disease; periostitis: bone disease
IT
     Alternate Indexing
```

Periostitis (MeSH)

```
IT • Miscellaneous Descriptors
       beekeeping: occupation
     Fuenlabrada de los Montes (Spain, Europe, Palearctic region)
GT
ORGN Super Taxa
       Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
        human (Hominidae): adult, aged, female, male, middle age, patient
ORGN Organism Superterms
       Animals; Chordates; Humans; Mammals; Primates; Vertebrates
L8
     ANSWER 7 OF 10 BIOSIS COPYRIGHT 2000 BIOSIS
AN
     1989:429996 BIOSIS
DN
     BA88:88254
ΤI
       ***BEE***
                     ***VENOM***
                                  THERAPY FOR
                                               ***ARTHRITIS***
ΑU
     KIM C M
CS
     MONMOUTH PAIN INST. INC., RED BANK, N.J., U.S.A. 07701.
SO
     RHUMATOLOGIE, (1989) 41 (3), 67-72.
     CODEN: RHUMAY.
FS
     BA; OLD
LA
     English
       ***Bee***
AB
                   ***Venom***
                                  therapy for ***arthritis***
     somewhat controversial. Unfortunately, there are very few controlled
     studies available to guide clinical practice. One Hundred and Eight
     patients with longstanding history of ***arthritis***
                                                              (RA or OA) who
     failed to respond to conventional medical treatment were used as subjects
     (Sept. 85 to Sept. 87). Participation was on a voluntary basis as denoted
     by informed consents from all subjects. All subjects were tested for
     possible allergic reaction before initial treatment. 0.1 ml. standard
     BV-10 was injected intradermally twice a week. The number of injections
     increased gradually each subsequent treatment until evaluation showed
     markedly improved or completely resolved.
                                                ***Pain***
                                                             was most common
     problem with subjects.
                             ***Pain***
                                          measure included the McGill
                   Questionnaire and Visual Analog Scales. Clinical evaluation
       ***Pain***
     included serial physical examinations and the thermographic findings. Each
     subject was followed 6 months to 2 years after finished treatment. Most of
     subjects, showed slight improvements after 3rd session and marked
     improvement average 12th treatment. Total 33,644 injections were given. No
     clinical complications or serious side effects were observed in any
     subjects who participated in the study. It was concluded the
       ***venom***
                   therapy is safe, effective and has no serious side effects,
     as long as a person is not allergic to ***bee***
                                                           ***venom***
     preliminary results highly suggest that ***bee***
                                                            ***venom***
     therapy is a new alternative approach for ***arthritis***
                                                                  victims who
     failed to respond to the conventional medical treatments.
CC
     Physical Anthropology; Ethnobiology *05000
     Social Biology; Human Ecology *05500
     Biochemical Studies - Proteins, Peptides and Amino Acids 10064
     Biophysics - General Biophysical Techniques 10504
     External Effects - Temperature as a Primary Variable - Hot
     Pathology, General and Miscellaneous - Diagnostic 12504
     Pathology, General and Miscellaneous - Inflammation and Inflammatory
     Disease *12508
     Pathology, General and Miscellaneous - Therapy
                                                     12512
     Bones, Joints, Fasciae, Connective and Adipose Tissue - General; Methods
     18001
     Bones, Joints, Fasciae, Connective and Adipose Tissue - Pathology
     Nervous System - Physiology and Biochemistry *20504
     Pharmacology - Clinical Pharmacology *22005
     Pharmacology - Connective Tissue, Bone and Collagen - Acting Drugs *22012
     Toxicology - General; Methods and Experimental *22501
     Immunology and Immunochemistry - Immunopathology, Tissue Immunology
     *34508
     Invertebrata, Comparative and Experimental Morphology, Physiology and
```

Pathology - Insecta - Physiology \*64076 Invertebrate Body Regions and Structures - Special Organs \*64218 BC Hymenoptera 75326 Hominidae 86215 ITMiscellaneous Descriptors HUMAN ANTIARTHRITIC ACTIONS \*\*\*PAIN\*\*\* RHEUMATOID \*\*\*ARTHRITIS\*\*\* QUESTIONNAIRE \*\*\*OSTEOARTHRITIS\*\*\* THERMOGRAPHY MCGILL \*\*\*PAIN\*\*\* VISUAL ANALOGUE SCALE FOLK MEDICINE ANSWER 8 OF 10 BIOSIS COPYRIGHT 2000 BIOSIS L8 AN 1987:391087 BIOSIS DN BR33:71227 \*\*\*VENOM\*\*\* ΤI \*\*\*BEE\*\*\* THERAPY FOR \*\*\*ARTHRITIS\*\*\* AND NEURALGIAS. ΑU KIM C M CS MONMOUTH PAIN INST., 46 ENGLISH PLAZA, RED BANK, N.J. SO FIFTH WORLD CONGRESS ON PAIN, HAMBURG, WEST GERMANY, AUGUST 2-7, 1987. PAIN. (1987) 0 (SUPPL 4), S262. CODEN: PAINDB. ISSN: 0304-3959. DT Conference FS BR; OLD LAEnglish CC General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520 Pathology, General and Miscellaneous - Inflammation and Inflammatory \*12508 Disease Pathology, General and Miscellaneous - Therapy 12512 Bones, Joints, Fasciae, Connective and Adipose Tissue - Pathology \*18006 Nervous System - Physiology and Biochemistry \*20504 Nervous System - Pathology \*20506 Pharmacology - Neuropharmacology \*22024 Invertebrata, Comparative and Experimental Morphology, Physiology and Pathology - Insecta - Physiology 64076 BCHominidae 86215 ΙT Miscellaneous Descriptors ABSTRACT HUMAN ANALGESIC-DRUG \*\*\*PAIN\*\*\* MCGILL \*\*\*PAIN\*\*\* QUESTIONNAIRE VISUAL ANALOG SCALES L8ANSWER 9 OF 10 MEDLINE AN2000072399 MEDLINE DN 20072399 ΤI Beekeeper' arthropathy. ΑU Cuende E; Fraguas J; Pena J E; Pena F; Garcia J C; Gonzalez M Rheumatology Unit, Hospital Txagorritxu, Vitoria, Pais Vasco, Spain. CS SO JOURNAL OF RHEUMATOLOGY, (1999 Dec) 26 (12) 2684-90. Journal code: JWX. ISSN: 0315-162X. CY Canada DT Journal; Article; (JOURNAL ARTICLE) LA English FS Priority Journals EM200004 EW 20000404 AB OBJECTIVE: To describe the clinical, analytical, and radiological features of an observed arthropathy affecting beekeepers. METHODS: Prospective study of 34 patients (32 male, 2 female), mean age 42 years (range 16 to 66 years), evaluated for the presence of acute or chronic related to beekeeping. All patients were working and \*\*\*arthritis\*\*\* living in the same village, Fuenlabrada de los Montes (1300 habitants), where there is a census of 180 beekeepers. An epidemiologic inquiry reported that > 50% of them reported episodes of \*\*\*arthritis\*\*\* the hands during the month of August, at the time of honey collection. RESULTS: Acute \*\*\*arthritis\*\*\* was observed in 10 patients. \*\*\*Pain\*\*\* , tenderness, joint swelling, and warmth were present in most

```
present in 16 cases, synovial thickening in 12, limited joint mobility in
     8, bony swelling in 15, and joint deformities in 13 patients. Radiological
     study showed periarticular soft tissue swelling, bone sclerosis,
     periostitis, bony erosions, subchondral cysts, geodes, osteophytes, and
     joint narrowing. CONCLUSION: Beekeepers have joint disease apparently
                  ***bee***
                             stings. Etiopathogenesis is unknown. Mechanical
               ***venom*** compounds, infection, and foreign body synovitis
     are factors that are thought to influence the pathogenesis of this
     syndrome. We designate the condition "beekeepers' arthropathy," and
     consider it an occupational disorder.
     Check Tags: Animal; Female; Human; Male
      Adolescence
      Adult
       ****Arthritis: EP, epidemiology***
       *** Arthritis: PA, pathology***
       *** Arthritis: RA, radiography***
       ****Bee Venoms: AE, adverse effects***
       *** Bees***
      Finger Joint: PA, pathology
      Finger Joint: RA, radiography
      Insect Bites and Stings
      Middle Age
     *Occupational Diseases: EP, epidemiology
      Occupational Diseases: PA, pathology
      Occupational Diseases: RA, radiography
      Prospective Studies
      Spain: EP, epidemiology
     0 ( ***Bee***
                        ***Venoms***
     ANSWER 10 OF 10 SCISEARCH COPYRIGHT 2000 ISI (R)
     1999:957443 SCISEARCH
     The Genuine Article (R) Number: 262ZP
     Beekeepers' arthropathy
     Cuende E (Reprint); Fraguas J; Pena J E; Pena F; Garcia J C; Gonzalez M
     HOSP TXAGORRITXU, RHEUMATOL UNIT, JOSE ATXOTEGUI S-N, VITORIA 01009, SPAIN
     (Reprint); HOSP PUERTA DE HIERRO, SERV RADIOL, MADRID, SPAIN; DON BENITO
     VILLANUEVA, ORTHOPED SURG SERV, BADAJOZ, SPAIN; DON BENITO VILLANUEVA,
     PRIMARY CARE HLTH AREA, BADAJOZ, SPAIN; HOSP TXAGORRITXU, RHEUMATOL UNIT,
     VITORIA 01009, SPAIN
     SPAIN
CYA
     JOURNAL OF RHEUMATOLOGY, (DEC 1999) Vol. 26, No. 12, pp. 2684-2690.
     Publisher: J RHEUMATOL PUBL CO, 920 YONGE ST, SUITE 115, TORONTO ON M4W
     3C7, CANADA.
     ISSN: 0315-162X.
     Article; Journal
     LIFE; CLIN
    English
REC
     Reference Count: 26
        Objective, To describe the clinical, analytical, and radiological
     features of an observed arthropathy affecting beekeepers.
        Methods. Prospective study of 34 patients (32 male, 2 female), mean age
    42 years (range 16 to 66 years), evaluated for the presence of acute or
              ***arthritis***
                                 related to beekeeping. All patients were
    working and living in the same village, Fuenlabrada de los Montes (1300
    habitants), where there is a census of 180 beekeepers. An epidemiologic
    inquiry reported that > 50% of them reported episodes of
                                                               ***arthritis***
    on the hands during the month of August, at the time of honey collection.
        Results. Acute
                         ***arthritis*** was observed in 10 patients.
       ***Pain*** , tenderness, joint swelling, and warmth were present in most
    cases. Chronic arthropathy was noted in 32 patients. Tenderness was
    present in 16 cases, synovial thickening in 12, limited joint mobility in
```

cases. Chronic arthropathy was noted in 32 patients. Tenderness was

CT

CN

L8

ΑN

GΑ

TI

ΑU

CS

SO

DT

FS

LA

AΒ

8, bony swelling in 15, and joint deformities in 13 patients. Radiological study showed periarticular soft tissue swelling, bone sclerosis, periostitis, bony erosions, subchondral cysts, geodes, osteophytes, and joint narrowing.

Conclusion. Beekeepers have joint disease apparently related to \*\*\*bee\*\*\* stings. Etiopathogenesis is unknown. Mechanical trauma, \*\*\*venom\*\*\* compounds, infection, and foreign body synovitis are factor that are thought to influence the pathogenesis of this syndrome. We designate the condition ''beekeepers' arthropathy,'' and consider it an occupational disorder.

CC RHEUMATOLOGY

סב

ST Author Keywords: beekeepers; \*\*\*arthritis\*\*\*

STP KeyWords Plus (R): RHEUMATOID- \*\*\*ARTHRITIS\*\*\* ; PHOSPHOLIPASE-A2;

\*\*\*VENOM\*\*\* ; PROTEIN; JOINTS

RE				
Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)
=======================================	\-\ / +=====-	' '	, (112 0 ) +======	\
ALTMAN R	1990	33	1601	ARTHRITIS RHEUM
ALTMAN R D	1984	27	277	ARTHRITIS RHEUM
BILLINGHAM M E J	1973	245	163	NATURE
BOMALASKI J S	1993	36	190	ARTHRITIS RHEUM
BOMALASKI J S	1995	154	4027	J IMMUNOL
BOMALASKI J S	1990	116	814	J LAB CLIN MED
CARRO A	1991	18	38	REV ESP RHEUMATOL
CHANG Y H	1979	9	205	AGENTS ACTIONS
CZARNETZKI B M	1990	85	505	J ALLERGY CLIN IMMUN
HABERMANN E	1972	177	314	SCIENCE
HADJIPETROUKOUR.L	1984	11	720	J RHEUMATOL
HADJIPETROUKOUR.L	1988	15	1126	J RHEUMATOL
JIROUT F	1998	25	109	REV ESP RHEUMATOL
LAWRENCE R C	1989	16	427	J RHEUMATOL
LORENZETTI O J	1972	4	339	RES COMMUN CHEM PATH
NEWNHAM R E	1991	7	89	NUTR HLTH
OLENGINSKI T P	1991	21	40	SEMIN ARTHRITIS RHEU
OWEN M D	1990	28	813	TOXICON
.PENA J	1995	105	164	MED CLIN-BARCELONA
PENA J	1989	37	227	VIDA APICOLA
REGINATO A J	1990	33	1753	ARTHRITIS RHEUM
RESNICK D	1989		379	BONE JOINT IMAGING
SHKENDEROV S	1982	20	317	TOXICON
TANNENBAUM H	1982	9.	649	J RHEUMATOL
VANSAASE J L C M	1989	48	271	ANN RHEUM DIS
WILLIAMS W V	1987	30	1362	ARTHRITIS RHEUM

## => d hits

'HITS' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT): end

## => d hit

L8 ANSWER 1 OF 10 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.

TI \*\*\*Bee\*\*\* \*\*\*venom\*\*\* provides \*\*\*pain\*\*\* relief.

CT Medical Descriptors:

<sup>\*</sup>analgesia

```
New Zealand
       ***arthritis: DT, drug therapy***
     drug marketing
     diet supplementation
     hormone synthesis
     antiinflammatory activity
    human
     clinical trial
    note
    Drug Descriptors:
       ****bee venom: CT, clinical trial***
       ****bee venom: DT, drug therapy***
       ****bee venom: PD, pharmacology***
     honey: DT, drug therapy
     nectar ease
=> d 16
    ANSWER 1 OF 126 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
     2000278919 EMBASE
                     ***venom***
       ***Bee***
                                   provides pain relief.
    Manufacturing Chemist, (2000) 71/8 (11).
     ISSN: 0262-4230 CODEN: MCHMDI
    United Kingdom
     Journal; Note
     030
             Pharmacology
     031
            Arthritis and Rheumatism
     037
            Drug Literature Index
    English
=> d l6 1-5
    ANSWER 1 OF 126 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
     2000278919 EMBASE
                    ***venom*** provides pain relief.
       ***Bee***
    Manufacturing Chemist, (2000) 71/8 (11).
     ISSN: 0262-4230 CODEN: MCHMDI
    United Kingdom
     Journal; Note
            Pharmacology
     030
     031
            Arthritis and Rheumatism
     037
            Drug Literature Index
    English
    ANSWER 2 OF 126 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
     2000204542 EMBASE
     Things do not get better by being left alone. The physician and
     complementary medicine.
     Perlman A.I.
    Dr. A.I. Perlman, Saint Barnabas Health Care System, Saint Barnabas
     Ambulatory Care Ctr., Livingston, NJ 07039, United States.
    Aperlman@sbhcs.com
     Journal of Rheumatology, (2000) 27/6 (1332-1333).
    Refs: 10
     ISSN: 0315-162X CODEN: JRHUA
     Canada
    Journal; Editorial
             Arthritis and Rheumatism
     031
     037
           Drug Literature Index
```

L6

AN

TI

SO

CY

DT

FS

LA

L6

AN

TI

SO

CY

DT.

FS

LA

L6 AN

TI

AU

CS

SO

CY

DT

FS

```
LA.
     English
L6
     ANSWER 3 OF 126 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
     1999425740 EMBASE
AN
TI
     Beekeepers' arthropathy.
     Cuende E.; Fraguas J.; Pena J.E.; Pena F.; Garcia J.C.; Gonzalez M.
ΑU
     Dr. E. Cuende, Unidad de Reumatologia, Hospital Txagorritxu, Jose
CS
     Atxotegui s/n, 01009 Vitoria, Spain
     Journal of Rheumatology, (1999) 26/12 (2684-2690).
SO
     ISSN: 0315-162X CODEN: JRHUA
CY
     Canada
DT
     Journal; Article
             Public Health, Social Medicine and Epidemiology
FS
             Arthritis and Rheumatism
     031
             Occupational Health and Industrial Medicine
     035
LΑ
     English
SL
     English
     ANSWER 4 OF 126 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
L6
     1999391245 EMBASE
AN
       ***Venoms*** , copper, and zinc in the treatment of ***arthritis***
TI
ΑU
     Caldwell J.R.
     Dr. J.R. Caldwell, Florida Arthritis and Allergy Inst., 311 North Clyde
CS
     Marris Boulevard, Daytona Beach, FL 32114, United States
SO
     Rheumatic Disease Clinics of North America, (1999) 25/4 (919-928).
     Refs: 38
     ISSN: 0889-857X CODEN: RDCAEK
CY
     United States
DT
     Journal; General Review
FS
             Pharmacology
             Arthritis and Rheumatism
     031
     037
             Drug Literature Index
     English
LA
\operatorname{SL}
     English
     ANSWER 5 OF 126 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
L6
AN
     1999206812 EMBASE
       ***Arthritis*** : New agents herald more effective symptom management.
ΤI
     Simon L.S.
ΑU
CS
     Dr. L.S. Simon, Graduate Medical Education, Beth Israel Deaconess Medical
     Center, Boston, MA, United States
SO
     Geriatrics, (1999) 54/6 (37-44).
     Refs: 15
     ISSN: 0016-867X CODEN: GERIAZ
CY
     United States
DT
     Journal; General Review
FS
     020
             Gerontology and Geriatrics
             Arthritis and Rheumatism
     031
     037
             Drug Literature Index
     038
             Adverse Reactions Titles
```

Melittin (honeybee) (9CI) (CA INDEX NAME) CN OTHER CA INDEX NAMES: CNMelittin (major) (8CI) OTHER NAMES: \*\*\*Bee venom melittin\*\*\* CNCN Forapin Forapine CN CNHoneybee melittin L-Glutamamide, glycyl-L-isoleucylglycyl-L-alanyl-L-valyl-L-leucyl-L-lysyl-CNL-valy1-L-leucy1-L-threony1-L-threonylglycy1-L-leucy1-L-proly1-L-alany1-Lleucyl-L-isoleucyl-L-seryl-L-tryptophyl-L-isoleucyl-L-lysyl-L-arginyl-Llysyl-L-arginyl-L-glutaminyl-CNMelittin Melittin (Apis cerana) CNCN Melittin I FS PROTEIN SEQUENCE; STEREOSEARCH DR 11030-50-5 C131 H229 N39 O31 MF CI COM LCSTN Files: AGRICOLA, AIDSLINE, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CHEMCATS, CIN, CSCHEM, EMBASE, MEDLINE, MRCK\*, MSDS-OHS, PROMT, RTECS\*, TOXLINE, TOXLIT, USPATFULL (\*File contains numerically searchable property data)

COPYRIGHT 2000 ACS

Apris melligera

ANSWER 1 OF 1 REGISTRY

20449-79-0 REGISTRY

684 REFERENCES IN FILE CA (1967 TO DATE)
50 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
686 REFERENCES IN FILE CAPLUS (1967 TO DATE)

4 00